Mass Spectrometry-Based Proteomics for Biomarker Discovery.

Area of Science:

• Proteomics
• Systems Medicine
• Pharmacology

Background:

• Proteomics is integral to systems medicine, enabling pharmacoproteomics and toxicoproteomics for drug efficacy and toxicity assessment.
• Quantitative proteomics, primarily using mass spectrometry, identifies and quantifies numerous proteins.
• This technology aids in biomarker discovery and elucidating drug action mechanisms.

Purpose of the Study:

• To describe a protocol for quantitative proteomic analysis using mass spectrometry.
• To highlight the application of proteomic techniques in systems medicine.
• To emphasize the role of mass spectrometry in drug efficacy and toxicity studies.

Main Methods:

• Quantitative proteomics utilizing mass spectrometry.
• Multidimensional liquid chromatography separation coupled with tandem mass spectrometry (LC-MS/MS).
• Stable isotope labeling (e.g., dimethyl labeling) and label-free approaches for protein/peptide quantitation.

Main Results:

• The described protocol, exemplified by dimethyl labeling and 2D-LC-MS/MS, enhances proteome coverage and depth.
• Mass spectrometry enables high-throughput identification and quantitation of thousands of proteins.
• Proteomic approaches facilitate biomarker discovery and understanding of drug mechanisms.

Conclusions:

• Mass spectrometry-based quantitative proteomics is a powerful tool for systems medicine.
• Advancements in proteomic technologies and increased sample throughput will further drive progress in systems medicine.
• Pharmacoproteomics and toxicoproteomics are key applications for evaluating drug effects.